Takeda Pharmaceutical Company Limited

Millennium Pharmaceuticals Limited

Catherine Scholz

Jason W Brown

Vaithianathan Palaniappan

Csanad M Varga

Willow Diluzio

Irving H Fox

Phuong Nguyen

Nobel T Truong

Willow Ruth Diluzio

Helen Jenkins

Maria Rosario

Erica Helen Jenkins

Phuong M Nguyen

Antibody formulations are described comprising a mixture of an anti-α4β7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

Treatment with anti-α4β7 antibody

Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.

Methods of treating ulcerative colitis

Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-α4β7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-α4β7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-α4β7 antibody in vivo.

Methods for treatment using anti-alpha4beta7 antibody

Growing community of inventors

Woburn, MA, United States of America

Catherine Scholz